Bring the immune system one step Ahead of cancer

An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology

0% of patients currently undergoing
treatment for solid tumors will experience treatment failure.

Our mission at Brenus is to provide a solution to patients with cold solid tumors – today’s biggest, unmet need in oncology.

Cancer = A moving target

The efficacy of current approaches is compromised by no anticipating tumor plasticity and relapsing mechanisms and must be combined to be efficient.

Our platform technology generates tailored first-in-class drug candidates by leveraging deep innovations to harness a multi-specific, highly potent & lasting immune response.

Represent heterogeneity of the targeted indication

Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.

Increase antigenicity

STC technology educates patient’s immune system with the widest range of tumor related AG linked to mechanism of relapse.

Increase immunogenicity

Haptenization process is a proven immunogenic tagging** sustainably boosting antigen’s immune recognition. It’s safely ensure immune system activation.

Stay tuned